Markets
Apimeds Pharmaceuticals US, Inc. (APUS)
APUSAMEXBiotechnology: Pharmaceutical Preparations
$2.60
-0.1050 (-3.88%) today
At the close, Nov 9, 4:00 PM ET. After hours $2.88 +6.22%
-3.88% 1D
- Market cap
- $4.18m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.61 to $2.73
- 52-week range
- $1.51 to $59.70
- Average volume
- –
- Previous close
- $2.71
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.84m | -$7.04m | -$12.19m | -$6.28m |
| Net income | -$1.78m | -$1.16m | -$35.06m | -$20.17m |
News
4 latest- Biotech Stocks On The Move - APUS, PFSA, GCTK, ARCT RTTNews · Sep 24, 2026
- APUS Stock Surges Over 130%; Apitox Phase 3 Path And Pipeline In Focus RTTNews · Sep 24, 2026
- Apimed Clears Path For Merger Completion And $100 Million PIPE Financing; Stock Down RTTNews · May 6, 2026
- Apimeds Pharmaceuticals US, Inc. Completes Initial Public Offering, Raising $13.5 Million for Clinical DevelopmentQuiver Quantitative · May 12, 2025
The company
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. For more information, visit www.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.